From our private database of 46,500+ case briefs, written and edited by humans—never with AI.
United States v. Bioclinical Systems, Inc.
United States District Court for the District of Maryland
666 F. Supp. 82 (1987)
- Written by Mary Phelan D'Isa, JD
Facts
The Food and Drug Administration (FDA) brought an enforcement action under the Federal Food, Drug, and Cosmetic Act (FDCA) against Bioclinical Systems, Inc. (BSI) (defendant), the manufacturer of plated culture media. The FDA alleged that BSI failed to meet the FDA’s Good Manufacturing Practices, (GMPs)—as dictated by the FDA Office of Compliance—regarding a sterility assurance level (SAL) of 0.1 percent. BSI challenged the requirement, which had been adopted as the de facto standard ever since a draft set Inspection Guidelines incorporating the standard was issued by the FDA’s Center for Devices and Radiological Health.
Rule of Law
Issue
Holding and Reasoning (Motz, J.)
What to do next…
Here's why 832,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 46,500 briefs, keyed to 994 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.
